Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has begun development of a novel formulation as a targeted prophylactic treatment. The company is developing the drug formulation in accordance with its sponsored research agreement with Columbia University. Designated as SPC-15, the treatment will be designed for stress, anxiety and PTSD. Stress-related disorders such as these are becoming more prevalent, with the World Health Organization reporting more than 300 million people struggle with an anxiety disorder. Fortune Business Insights is projecting that the global treatment market size for anxiety disorders and depression will reach $13 billion by 2027. Silo Pharma has a U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females, and studies indicate that SPC-15 exhibits promise as a potential therapeutic target for the treatment of cognitive impairment, PTSD and stress-related disorders. “We are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,” said Silo Pharma CEO Eric Weisblum in the press release. “The SPC-15 treatment protocol predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers’ response to pharmacological treatments. Based on our own research to date coupled with published preclinical data, we believe SPC-15 could have a profound impact on treating stress and anxiety disorders including PTSD, we will further use this data to help us with our upcoming studies related to SPC-14 Alzheimer’s asset.”
To view the full press release, visit https://ibn.fm/xgbQJ
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications for people suffering from indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
